ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension

• Status: Recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this project is to conduct a randomized, controlled trial (RCT) to determine if choice of antihypertensive medication influences changes in functional status and other cardiovascular risk factors among older persons with hypertension when combined with physical exercise.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alabama at Birmingham
• Collaborators: Translational Research Institute for Metabolism and Diabetes, Advent Health; University of Colorado, Denver
• Treatments: Antihypertensive Agents; Losartan; Perindopril

Criteria

Inclusion Criteria:

• Age 60 years and older

• Hypertension - untreated (SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg) or treated

• > 290 seconds needed to complete long-distance corridor walk test

• Sedentary lifestyle, defined as <150 min/wk of moderate physical activity

• Willingness to participate in all study procedures, including allowing study team to communicate with primary care physician regarding changes in antihypertensive treatment

Exclusion Criteria:

• BP > 140/90, despite the use of three or more anti-hypertensive drugs

• SBP > 180 mm Hg or DBP > 110 mm Hg

• Chronic kidney disease

• Serum creatinine >2.5 mg/dL in men or >2.0 mg/dL in women

• Serum potassium outside normal reference range

• Urinary protein > 1 on dipstick

• Abnormal liver enzymes (AST, ALT, or alkaline phosphatase > 2.5 times the upper limit of normal)

• Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina

• Acute myocardial infarction identified by ECG

• Significant cognitive impairment, defined as a known diagnosis of dementia or a Mini-Mental State Examination exam score < 24;

• Simultaneous participation in another intervention trial

• Known hypersensitivity to ACE inhibitors (exclusion only to perindopril arm; will be randomized among other two interventions)

• Any other condition that would preclude participating based upon judgement of PI or study clinician team